Jaime Merchan
Co-Leader, Translational and Clinical Oncology Research Program, Sylvester Comprehensive Cancer Center · University of Miami/Jackson Health System
Credentials: · · · · ·
History
- Present
Translational and Clinical Oncology Research Program · University of Miami/Jackson Health System
- Present
Phase 1 Clinical Trials Program · University of Miami/Jackson Health System
- 1995–1997
Medical Oncology
- 1992–1995
Internal Medicine
- 1988–1992
Doctor of Medicine
Research
Journal of Clinical Investigation · 2003 · 3,226 citations
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
New England Journal of Medicine · 2013 · 1,518 citations
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
New England Journal of Medicine · 2021 · 1,467 citations
11 papers
10 papers
- RP
8 papers
- JL
7 papers
- RM
7 papers
7 papers
6 papers
6 papers
Grants
- 2011–2017
Tumor and Stromal Targeting by Oncolytic Viruses
National Cancer Institute · R01
Contact PI · $1.7M · University of Miami School of Medicine
- 2006–2009
Biomarkers for VEGF and mTOR Blockade in Advanced Renal Cancer
National Cancer Institute · R21
Contact PI · $452.1K · University of Miami School of Medicine
Clinical trials
- 2016–2019
Principal investigator · Terminated · Phase 1
Tocagen Inc.
- 2008–2015
Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
Principal investigator · Completed · Phase 1
Jaime Merchan
- 2005–2015
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
Principal investigator · Completed · Phase 1, Phase 2
National Cancer Institute (NCI)
- 2025–2027
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)